FDA, Zepbound and Tirzepatide

FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to cheaper versions could end.
FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.
FDA says tirzepatide shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for these medications.
FDA approves Zepbound for sleep apnea in obese adults
Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.
FDA approves new drug for sleep apnea
The drug is known as Zepbound and is the same as the chemical drug Tirzepatide. "See To Believe uncovers the forgotten, mind-blowing facts that will leave you questioning everything. Follow wild stories of mysterious creatures,
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
TCTMD10h
TCTMD’s Top 10 Most Popular Stories for December 2024
Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...
AOL4d
What is Compounded Tirzepatide? Here's What You Need to Know
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. If you’re starting a weight loss journey, you might have ...
MedPage Today11d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry Leaders
Following billionaire investors isn't as difficult as you might imagine thanks to quarterly reporting required by the ...
Pharmaceutical Technology1d
Tirzepatide by Eli Lilly and Co for Obesity: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Dr. Roach: Ozempic dosage can be increased if/when a plateau is reached
Wegovy and Ozempic are the exact same drug: semaglutide. They are dosed slightly differently and marketed for different ...
Beyond obesity: How weight loss drugs lowered heart disease, kidney and liver disease in trials this year
Eli Lilly and Novo Nordisk are likely to introduce its popular injectable drugs semaglutide and tirzepatide in India in 2025.